What is the difference between “DILIsym®” and “DILI-sim”?
“DILIsym®” is a registered trademark for computer modeling software (DILIsym® software) and for consulting services (DILIsym® Services).
“DILI-sim” refers to the DILI-sim Initiative, a consortium of life science companies led by DILIsym Services, Inc., that is charged with developing the DILIsym® software.
1. What inputs do I need to run the model for my compound?
DILIsym® is designed to utilize inputs ranging from in vitro data to clinical results. A recent DILIsym® publication related to methapyrilene demonstrates the use of in vitro data with the model, while a publication on acetaminophen treatment shows the utilization of clinical data.
2. How is the model validated?
In 2012, the first version of the DILIsym® modeling software was released (v1A). The released model focused on DILI mediated through the depletion of ATP levels in hepatocytes, with emphasis on oxidative stress induced by reactive metabolites. DILIsym® v4B was released in 2015, and includes additional DILI mechanisms related to bile acid homeostasis disruption and mitochondrial dysfunction. Resources utilized to optimize and validate the model include scientific literature, novel experiments, clinical trials and reports, expert opinions, and basic biological principles. To facilitate review of the quantitative data sets utilized to build the model, each DILIsym® version includes a Data Comparisons feature that displays comparisons of simulation results with data sets used to optimize, validate, or test the model.
3. On what software platform is the model based?
DILIsym® is based in MATLAB (MathWorks, Inc.).
4. Is the model available publicly?
The DILI-sim Initiative is currently open to new members. Please contact us for more information on joining. Through membership, corporate entities can receive access to DILIsym®. Academic and non-profit researchers are also encouraged to contact the DILI-sim modeling team at DILIsym Services, Inc. to receive information on accessing DILIsym® modeling software.
The DILI-sim Initiative
1. How can my organization get involved?
The DILI-sim Initiative is currently open to new members. Please contact us for more information on joining.
2. Is there a Scientific Advisory Board?
The DILI-sim Initiative efforts are reviewed by a stellar scientific advisory board. Click here to see the members of the board.
3. How do DILI-sim members influence DILIsym® software development?
The DILI-sim consortium members approve the particular aspects of model development, ultimately shaping DILIsym® to focus on areas of immediate importance to drug development. Future directions are determined by the availability of data and the priorities of the DILI-sim consortium members.
4. What are the benefits of joining the DILI-sim Initiative?
DILI-sim members are given access to the most up-to-date version of the DILIsym® modeling software, along with training and support from the DILI-sim modeling team. Furthermore, members receive discounts on consulting services provided by the DILI-sim modeling team. Access is also granted to the members' section of the DILIsym.com website, where the model and documentation can be downloaded and the members' forum can be accessed. The members' forum provides a medium for posting and reading technical and operational questions and answers, as well as engaging in interesting scientific discussions.